Biogen Inc.

(BIIB) Trade

By |

Profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Contact Information

Website: www.biogen.com
Email: IR@biogen.com
Main Phone: +1 617 679-2000
Address: 225 Binney Street
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: Michel Vounatsos
Employees: 7300
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 316.73 $ -9.97 (-3.05%)
Last Price 316.73 Change $ -9.97 Change % -3.05 Tick N/A
Bid 309.36 Bid Size 100.00 Ask 320.99 Ask Size 100.00
Open 324.60 High 326.55 Low 316.15 Prev Close 326.70
Last Trade Volume 1.2 mi 52 Wk Hi 388.67 52 Wk Low 249.17
Market Cap 63.8 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 201,482,595.00 EPS (TTM) 15.49 PE Ratio 20.40 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 15
Number of Buys 0 7
Number of Sells 0 8
Net Activity 0 21184
Last 10 Buys Shares
Michel Vounatsos 1,000
Alexander J. Denner, 1,000
Alexander J. Denner, 1,000
Michel Vounatsos 1,000
Alexander J. Denner, 1,000
Alexander J. Denner, 1,000
Michel Vounatsos 1,000
Alexander J. Denner, 1,000
Alexander J. Denner, 1,000
Stelios Papadopoulos 1,000
Last 10 Sell Shares
Robert W. Pangia 1,000
Susan H. Alexander 1,000
Susan H. Alexander 1,000
Brian S. Posner 1,000
Paul J. Clancy 1,000
Alfred W. Sandrock 1,000
Paul J. Clancy 1,000
Alfred W. Sandrock 1,000
Robert W. Pangia 1,000
Adriana Karaboutis 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 433 433 433 433
Low Target Price Estimate 272 272 272 272
Mean Target Price Estimate 348.83 349.45 349.45 350.39
Standard Deviation 43.74 44.67 44.67 43.23
Date of Most Recent Estimate 05/31/18 05/07/18 05/07/18 05/31/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 16 16 15 15
Moderate Buy 1 1 1 1
Hold 7 7 8 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.6 1.6 1.69 1.63